Jain Global’s Celldex Therapeutics CLDX Stock Holding History

Jain Global’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,763	Closed	-$246K	–	1782
2026 Q1	$246K	Buy	+7,763	New	+$212K	﹤0.01%	1051

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jain Global's CLDX Position: Q2 2026 in Review

Jain Global sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 7,763 shares — an estimated $246K sold.

Jain Global first reported a position in CLDX in Q1 2026 and held it in 1 quarter. The position peaked at $246K in Q1 2026. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Jain Global reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
Jain Global sold 7,763 Celldex Therapeutics shares in Q2 2026, an estimated $246K.
Jain Global first reported a position in Celldex Therapeutics in Q1 2026 and held it in 1 quarter.
Jain Global's Celldex Therapeutics position peaked at $246K in Q1 2026.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.